A Phase 1 interventional study of Nalmefene hydrochloride and Naloxone hydrochloride in Pharmacodynamic, sponsored by Opiant Pharmaceuticals Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-14.
Sponsored by Opiant Pharmaceuticals Inc (part of Indivior Pharmaceuticals, Inc.) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is to determine the pharmacodynamics (the effects of the drug and mechanisms of their action within the body) of Nalmefene when given intranasally (IN; into the nose) compared to intranasal naloxone when given to healthy volunteers under steady state opioid agonism.
Open-label, 2-part study. Part 1 is a pilot study to determine the relationship between opioid agonism and suppression of carbon dioxide induced increases in minute ventilation prior to opioid exposure. Part 2 will be a randomized, 2 period, 2 treatment, crossover study to evaluate the pharmacodynamic effects of intranasal (IN) nalmefene compared to IN naloxone to reverse opioid-induced suppression of carbon dioxide induced increases in minute ventilation, in healthy volunteers with prior opioid exposure.
Both Part 1 and Part 2 of the study will consist of an outpatient Screening Visit taking place 28 days prior to admission, an in-clinic Treatment Phase consisting of a 6 or 7 day inpatient stay, and a Follow-Up Phone Call conducted 3 to 7 days after discharge.
Opiant Pharmaceuticals Inc is the lead sponsor of 3 studies on the registry; none are open to participants now.
First submitted before Opiant Pharmaceuticals Inc became part of Indivior Pharmaceuticals, Inc..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nalmefene hydrochloride nasal spray, 3mg, 1 spray
Drug: Nalmefene hydrochloride
Naloxone hydrochloride nasal spray, 4mg, 1 spray
Drug: Naloxone hydrochloride
3mg Nasal spray
4mg Nasal Spray
Change in Minute Ventilation
Change in minute ventilation from opioid induced nadir
Time frame: 5 minutes
Maximum Change in Minute Ventilation
Maximum change in minute ventilation from opioid induced nadir
Time frame: Up to 2 hours
Time to Maximum Change in Minute Ventilation
Time to maximum change in minute ventilation from opioid induced nadir
Time frame: Up to 2 hours
Change in Minute Ventilation
Change in minute ventilation from opioid induced nadir
Time frame: 90 minutes
Change in Minute Ventilation
Change in minute ventilation from opioid induced nadir
Time frame: 20 minutes
Change in Minute Ventilation
Change in minute ventilation from opioid induced nadir
Time frame: 15 minutes
Change in Minute Ventilation
Change in minute ventilation from opioid induced nadir
Time frame: 10 minutes
Change in Minute Ventilation
Change in minute ventilation from opioid induced nadir
Time frame: 2.5 minutes
| Milestone | Part 1 Setup (Ventilation Model): Remifentanil, Then Intranasal Naloxone | Part 1 Extension Setup (Ventilation Model): Remifentanil, Then Intranasal Naloxone | Part 2: Intranasal Nalmefene Crossover to Intranasal Naloxone | Part 2: Intranasal Naloxone Crossover to Intranasal Nalmefene |
|---|---|---|---|---|
| Started | 7 | 0 | 0 | 0 |
| Completed | 7 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Part 1 Setup (Ventilation Model): Remifentanil, Then Intranasal Naloxone | Part 1 Extension Setup (Ventilation Model): Remifentanil, Then Intranasal Naloxone | Part 2: Intranasal Nalmefene Crossover to Intranasal Naloxone | Part 2: Intranasal Naloxone Crossover to Intranasal Nalmefene |
|---|---|---|---|---|
| Started | 7 | 0 | 0 | 0 |
| Completed | 5 | 0 | 0 | 0 |
| Not completed | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 0 |
| Milestone | Part 1 Setup (Ventilation Model): Remifentanil, Then Intranasal Naloxone | Part 1 Extension Setup (Ventilation Model): Remifentanil, Then Intranasal Naloxone | Part 2: Intranasal Nalmefene Crossover to Intranasal Naloxone | Part 2: Intranasal Naloxone Crossover to Intranasal Nalmefene |
|---|---|---|---|---|
| Started | 5 | 0 | 0 | 0 |
| Completed | 5 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Part 1 Setup (Ventilation Model): Remifentanil, Then Intranasal Naloxone | Part 1 Extension Setup (Ventilation Model): Remifentanil, Then Intranasal Naloxone | Part 2: Intranasal Nalmefene Crossover to Intranasal Naloxone | Part 2: Intranasal Naloxone Crossover to Intranasal Nalmefene |
|---|---|---|---|---|
| Started | 0 | 8 | 0 | 0 |
| Completed | 0 | 8 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Part 1 Setup (Ventilation Model): Remifentanil, Then Intranasal Naloxone | Part 1 Extension Setup (Ventilation Model): Remifentanil, Then Intranasal Naloxone | Part 2: Intranasal Nalmefene Crossover to Intranasal Naloxone | Part 2: Intranasal Naloxone Crossover to Intranasal Nalmefene |
|---|---|---|---|---|
| Started | 0 | 0 | 34 | 35 |
| Completed | 0 | 0 | 27 | 32 |
| Not completed | 0 | 0 | 7 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 1 |
| Withdrew: Adverse event | 0 | 0 | 3 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 2 | 1 |
| Withdrew: Equipment failure | 0 | 0 | 0 | 1 |
| Milestone | Part 1 Setup (Ventilation Model): Remifentanil, Then Intranasal Naloxone | Part 1 Extension Setup (Ventilation Model): Remifentanil, Then Intranasal Naloxone | Part 2: Intranasal Nalmefene Crossover to Intranasal Naloxone | Part 2: Intranasal Naloxone Crossover to Intranasal Nalmefene |
|---|---|---|---|---|
| Started | 0 | 0 | 27 | 32 |
| Completed | 0 | 0 | 25 | 30 |
| Not completed | 0 | 0 | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 2 |
| Milestone | Part 1 Setup (Ventilation Model): Remifentanil, Then Intranasal Naloxone | Part 1 Extension Setup (Ventilation Model): Remifentanil, Then Intranasal Naloxone | Part 2: Intranasal Nalmefene Crossover to Intranasal Naloxone | Part 2: Intranasal Naloxone Crossover to Intranasal Nalmefene |
|---|---|---|---|---|
| Started | 0 | 0 | 25 | 30 |
| Completed | 0 | 0 | 25 | 27 |
| Not completed | 0 | 0 | 0 | 3 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
Change in minute ventilation from opioid induced nadir
| L/min | Intranasal Naloxone | Intranasal Nalmefene |
|---|---|---|
| Change in Minute Ventilation | 3.432 ± 0.6117 | 5.744 ± 0.6240 |
Maximum change in minute ventilation from opioid induced nadir
| ng/mL | Intranasal Nalmefene | Intranasal Naloxone |
|---|---|---|
| Maximum Change in Minute Ventilation | 6.8 ± 2.7 | 5.8 ± 3.0 |
Time to maximum change in minute ventilation from opioid induced nadir
| hour | Intranasal Nalmefene | Intranasal Naloxone |
|---|---|---|
| Time to Maximum Change in Minute Ventilation | 0.50 (0.04 to 2.00) | 0.75 (0.13 to 2.00) |
Change in minute ventilation from opioid induced nadir
| L/min | Intranasal Nalmefene | Intranasal Naloxone |
|---|---|---|
| Change in Minute Ventilation | 2.71 ± 0.59 | 2.14 ± 0.62 |
Change in minute ventilation from opioid induced nadir
| L/min | Intranasal Nalmefene | Intranasal Naloxone |
|---|---|---|
| Change in Minute Ventilation | 6.79 ± 0.71 | 5.93 ± 0.68 |
Change in minute ventilation from opioid induced nadir
| L/min | Intranasal Nalmefene | Intranasal Naloxone |
|---|---|---|
| Change in Minute Ventilation | 7.12 ± 0.77 | 5.55 ± 0.64 |
Change in minute ventilation from opioid induced nadir
| L/min | Intranasal Nalmefene | Intranasal Naloxone |
|---|---|---|
| Change in Minute Ventilation | 6.58 ± 0.66 | 4.96 ± 0.69 |
Change in minute ventilation from opioid induced nadir
| L/min | Intranasal Nalmefene | Intranasal Naloxone |
|---|---|---|
| Change in Minute Ventilation | 2.55 ± 0.38 | 1.71 ± 0.53 |
Collected over Crossover study adverse event data collected form baseline through to day 6 with a +3 to 7 day follow-up. During the 6 day dosing they took either nalmefene or naloxone on day 1 followed by a 3 day washout and the other dose on day 5. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intranasal Nalmefene | 0/61 (0%) | 0/61 (0%) | 56/61 (91.8%) |
| Intranasal Naloxone | 0/60 (0%) | 0/60 (0%) | 52/60 (86.7%) |
| Event | Intranasal Nalmefene | Intranasal Naloxone |
|---|---|---|
| HeadacheNervous system disorders | 36/61 | 35/60 |
| NauseaGastrointestinal disorders | 24/61 | 25/60 |
| VomitingGastrointestinal disorders | 7/61 | 14/60 |
| Hot FlushVascular disorders | 14/61 | 7/60 |
| DizzinessNervous system disorders | 11/61 | 13/60 |
| AnxietyPsychiatric disorders | 10/61 | 4/60 |
| FatigueGeneral disorders | 6/61 | 2/60 |
| DysgeusiaNervous system disorders | 2/61 | 5/60 |
| Nasal discomfortRespiratory, thoracic and mediastinal disorders | 5/61 | 0/60 |
| SomnolenceNervous system disorders | 2/61 | 4/60 |
| Age, Customized(years) | Part 1: Intranasal Nalmefene | Part 1 Extension: Intranasal Nalmefene | Part 2: Intranasal Nalmefene Compared to Intranasal Naloxone | Total |
|---|---|---|---|---|
| Mean | 28.6 ± 4.50 | 29.1 ± 11.05 | 29.1 ± 7.79 | 29.1 ± 7.84 |
| Sex: Female, Male(Participants) | Part 1: Intranasal Nalmefene | Part 1 Extension: Intranasal Nalmefene | Part 2: Intranasal Nalmefene Compared to Intranasal Naloxone | Total |
|---|---|---|---|---|
| Female | 1 | 2 | 21 | 24 |
| Male | 6 | 6 | 48 | 60 |
| Race/Ethnicity, Customized(Participants) | Part 1: Intranasal Nalmefene | Part 1 Extension: Intranasal Nalmefene | Part 2: Intranasal Nalmefene Compared to Intranasal Naloxone | Total |
|---|---|---|---|---|
| White | 6 | 6 | 57 | 69 |
| Black or African American | 1 | 2 | 6 | 9 |
| Asian | 0 | 0 | 2 | 2 |
| American Indian or Alaskan Native | 0 | 0 | 3 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Not Reported | 0 | 0 | 0 | 0 |
| Unknown | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Part 1: Intranasal Nalmefene | Part 1 Extension: Intranasal Nalmefene | Part 2: Intranasal Nalmefene Compared to Intranasal Naloxone | Total |
|---|---|---|---|---|
| United States | 7 | 8 | 69 | 84 |
| BMI(kg/m2) | Part 1: Intranasal Nalmefene | Part 1 Extension: Intranasal Nalmefene | Part 2: Intranasal Nalmefene Compared to Intranasal Naloxone | Total |
|---|---|---|---|---|
| Mean | 25.03 ± 3.338 | 24.48 ± 3.665 | 25.27 ± 3.316 | 25.17 ± 3.317 |
| Weight(kg) | Part 1: Intranasal Nalmefene | Part 1 Extension: Intranasal Nalmefene | Part 2: Intranasal Nalmefene Compared to Intranasal Naloxone | Total |
|---|---|---|---|---|
| Mean | 79.13 ± 16.616 | 78.65 ± 9.735 | 78.30 ± 14.120 | 78.40 ± 13.833 |
| Height(cm) | Part 1: Intranasal Nalmefene | Part 1 Extension: Intranasal Nalmefene | Part 2: Intranasal Nalmefene Compared to Intranasal Naloxone | Total |
|---|---|---|---|---|
| Mean | 178.7 ± 9.71 | 179.8 ± 9.38 | 175.6 ± 10.21 | 176.3 ± 10.08 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2021 to primary completion in Mar 2022, 11 months.
Results were first posted in Jul 2025, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nalmefene